Does PEMBROLIZUMAB Cause Product use in unapproved indication? 3,191 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 3,191 reports of Product use in unapproved indication have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 3.8% of all adverse event reports for PEMBROLIZUMAB.
3,191
Reports of Product use in unapproved indication with PEMBROLIZUMAB
3.8%
of all PEMBROLIZUMAB reports
514
Deaths
909
Hospitalizations
How Dangerous Is Product use in unapproved indication From PEMBROLIZUMAB?
Of the 3,191 reports, 514 (16.1%) resulted in death, 909 (28.5%) required hospitalization, and 138 (4.3%) were considered life-threatening.
Is Product use in unapproved indication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 3,191 reports have been filed with the FAERS database.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Malignant neoplasm progression (10,111)
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
Hypothyroidism (2,326)
What Other Drugs Cause Product use in unapproved indication?
DUPILUMAB (33,452)
DICLOFENAC (12,197)
METHOTREXATE (8,930)
PREDNISONE (7,625)
RITUXIMAB (7,519)
MYCOPHENOLATE MOFETIL (5,910)
ACETAMINOPHEN (5,819)
CYCLOPHOSPHAMIDE (5,750)
RISPERIDONE (5,551)
TACROLIMUS (5,057)
Which PEMBROLIZUMAB Alternatives Have Lower Product use in unapproved indication Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G